IMpower030: Strong EFS and Pathologic Responses, but No Confirmatory Statistical Win

Perioperative atezolizumab plus platinum-based chemotherapy delivered a large numerical improvement in event-free survival (EFS) and markedly improved pathologic tumor responses in the final Phase 3 IMpower030 analysis. But the trial did not cross its prespecified statistical-significance boundary for the primary EFS endpoint—a distinction that matters for regulatory decisions and treatment guidelines. 45

What IMpower030 studied

IMpower030 evaluated atezolizumab given with platinum-based chemotherapy before surgery, followed by atezolizumab after surgery, in patients with resectable stage IIB–IIIB non-small cell lung cancer (NSCLC) without EGFR or ALK alterations. The final analysis was presented at the IASLC 2026 World Conference on Lung Cancer in Seoul. 45

Efficacy: a 27.9-month median EFS difference

After a median follow-up of 69.3 months, independently reviewed median EFS was 62.8 months with perioperative atezolizumab plus chemotherapy and 34.9 months with placebo plus chemotherapy. That is an absolute difference of 27.9 months. 45

The reported EFS hazard ratio was 0.70 (95% CI, 0.53–0.93), favoring the atezolizumab regimen. However, the analysis did not satisfy the trial's prespecified statistical-significance requirement for its primary endpoint. 4

That means the findings show a clinically notable numerical advantage, but they do not provide formal confirmatory proof under the study's statistical plan.

Pathologic responses were substantially higher

Tumor response at surgery also favored the atezolizumab group:

• Pathologic complete response (pCR): 29.6% with atezolizumab plus chemotherapy versus 8.5% with placebo plus chemotherapy.
• Major pathologic response (MPR): 53.6% versus 24.4%, respectively. 7

In this trial, pCR refers to no viable tumor cells identified in the resected primary tumor and sampled lymph nodes, while MPR is defined as 10% or less residual viable tumor in the primary tumor. 3

These response differences reinforce that adding atezolizumab increased preoperative antitumor activity. Pathologic response, however, is not interchangeable with a demonstrated overall-survival benefit.

Disease-free survival and overall survival

Investigator-assessed EFS, disease-free survival (DFS), and overall survival (OS) numerically favored perioperative atezolizumab in conference reporting. Available reports did not establish a statistically significant OS advantage or provide mature definitive OS results. 45

As a result, the final analysis is most appropriately read as a favorable but statistically nonconfirmatory efficacy signal, rather than conclusive evidence that the regimen improves survival for every eligible patient.

Safety and surgical feasibility

No new safety signals were identified in the final analysis. Surgical cancellation rates were low and similar between treatment groups: 11.1% with atezolizumab plus chemotherapy and 10.3% with placebo plus chemotherapy.

The similarity in cancellation rates is important because it suggests that, within this trial, adding perioperative atezolizumab did not create a clear overall barrier to proceeding with planned surgery. Conference reporting also indicated that adverse events were more common during the neoadjuvant phase than during the postoperative treatment phase in both groups. 4

Why the missed significance threshold changes the interpretation

The EFS and pathologic-response differences are clinically compelling, especially in a setting where preventing recurrence after surgery is a central treatment goal. Still, a favorable hazard ratio and large median difference do not override a prespecified statistical testing boundary.

For regulators and guideline panels, the result is therefore supportive rather than standalone confirmatory evidence. Any future decision would need to weigh the total evidence base: the magnitude and durability of EFS benefit, pathological responses, mature survival follow-up, safety, surgical outcomes, and evidence from other perioperative immunotherapy studies.

Bottom line

IMpower030 found that perioperative atezolizumab plus platinum chemotherapy was associated with longer median EFS—62.8 versus 34.9 months—and much higher pCR and MPR rates than chemotherapy plus placebo in resectable stage IIB–IIIB NSCLC without EGFR or ALK alterations. 457

Yet because the primary EFS analysis missed its prespecified significance threshold, the study does not by itself establish the regimen as a new standard for all patients. The results are important for multidisciplinary discussions and future evidence reviews, while longer-term survival data remain especially consequential. 45